<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Inborn errors of metabolism: Classification
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Inborn errors of metabolism: Classification
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Inborn errors of metabolism: Classification
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            V Reid Sutton, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sihoun Hahn, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth TePas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 26, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Congenital metabolic disorders result from the absence or abnormality of an enzyme or its cofactor or, less frequently, a gene product that modulates the metabolic pathway through different mechanisms, such as substrate transport, leading to either accumulation or deficiency of a specific metabolite  (
         <a class="graphic graphic_table graphicRef82924" href="/z/d/graphic/82924.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef56040" href="/z/d/graphic/56040.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef69937" href="/z/d/graphic/69937.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef74261" href="/z/d/graphic/74261.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_table graphicRef63392" href="/z/d/graphic/63392.html" rel="external">
          table 5
         </a>
         and
         <a class="graphic graphic_table graphicRef114663" href="/z/d/graphic/114663.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p>
         The major classes of inborn errors of metabolism (IEM) and their characteristic clinical and biochemical features are described below. The epidemiology, pathogenesis, clinical presentation, evaluation, and initial management of IEM are discussed separately, as are specific disorders. (See
         <a class="medical medical_review" href="/z/d/html/2912.html" rel="external">
          "Metabolic emergencies in suspected inborn errors of metabolism: Presentation, evaluation, and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2936.html" rel="external">
          "Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17216.html" rel="external">
          "Inborn errors of metabolism: Identifying the specific disorder"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CLASSIFICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The traditional classification system for IEM groups the disorders according to the general type of metabolism involved. Some diseases fit into more than one category. These major categories can be further grouped based upon similarities in pathogenesis and/or presenting features  (
         <a class="graphic graphic_table graphicRef82924" href="/z/d/graphic/82924.html" rel="external">
          table 1
         </a>
         ). Other, more detailed nosologies for the classification of IEM that are biochemistry based have been established [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2936.html" rel="external">
          "Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2912.html" rel="external">
          "Metabolic emergencies in suspected inborn errors of metabolism: Presentation, evaluation, and management"
         </a>
         .)
        </p>
        <p>
         Peroxisomal and lysosomal storage disorders, for example, often have characteristic clinical features and permanent, progressive symptoms that are independent of triggering events (eg, anemia, thrombocytopenia, and hepatomegaly in a child of Ashkenazi Jewish ancestry is suggestive of Gaucher disease) [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2918.html" rel="external">
          "Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
         The other categories of IEM (amino acid disorders, organic acidemias, urea cycle disorders [UCDs], disorders of carbohydrate metabolism, fatty acid oxidation disorders, and mitochondrial disorders) may be considered in two broad categories [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disorders of acute or progressive intoxication or encephalopathy
         </strong>
         – Signs and symptoms in these disorders are caused by accumulation of toxic compounds proximal to the metabolic block. Patients typically present with a symptom-free interval followed by clinical signs of acute or chronic intoxication with progressive or recurrent metabolic disturbances. This category includes amino acid disorders, most organic acidemias, UCDs, and disorders of carbohydrate intolerance (eg, galactosemia, hereditary fructose intolerance).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disorders associated with energy deficiency
         </strong>
         – Signs and symptoms in these disorders are caused at least partly by a deficiency in energy production or utilization in the liver, myocardium, skeletal muscle, or brain. Disorders in this category also may have signs or symptoms related to accumulation of toxic compounds. This category includes disorders of glycogenolysis and gluconeogenesis, fatty acid oxidation defects, disorders of ketogenesis, and mitochondrial disorders.
        </p>
        <p>
        </p>
        <p>
         The major categories of IEM are described below, with examples of representative disorders. Individual clinical and laboratory presenting features of IEM are discussed in detail separately, as is a detailed discussion on initial and specific diagnostic evaluation. (See
         <a class="medical medical_review" href="/z/d/html/2912.html" rel="external">
          "Metabolic emergencies in suspected inborn errors of metabolism: Presentation, evaluation, and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2936.html" rel="external">
          "Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17216.html" rel="external">
          "Inborn errors of metabolism: Identifying the specific disorder"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Amino acid disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Amino acids are important for the synthesis of numerous compounds, including structural proteins, peptide hormones, and enzymes needed for gluconeogenesis or in the generation of energy via acetyl coenzyme A (acetyl-CoA) formation. Of the 20 amino acids, 11 can be synthesized in vivo and 9 cannot. The nine that cannot be synthesized in vivo are called "essential amino acids." Their bioavailability relies completely upon dietary intake  (
         <a class="graphic graphic_table graphicRef61661" href="/z/d/graphic/61661.html" rel="external">
          table 7
         </a>
         ).
        </p>
        <p>
         Amino acid disorders (also called amino acidopathies) are caused by a defect in the metabolic pathways of amino acids. They are called amino acidemias when there is abnormal accumulation of amino acids in the plasma and amino acidurias when there is abnormal excretion of amino acids in the urine. Symptoms typically result from accumulation of the substance that cannot be metabolized. Examples of amino acid disorders include maple syrup urine disease and phenylketonuria. (See
         <a class="medical medical_review" href="/z/d/html/2922.html" rel="external">
          "Overview of maple syrup urine disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2919.html" rel="external">
          "Overview of phenylketonuria"
         </a>
         .)
        </p>
        <p>
         Amino acid disorders often present in newborns who are initially well and become acutely symptomatic (metabolic decompensation with poor feeding and lethargy) after a period of protein feeding. The symptoms may progress to encephalopathy, coma, or death if not recognized and treated promptly [
         <a href="#rid3">
          3
         </a>
         ]. In older children, developmental delay or regression is usually present. Many amino acid disorders can be detected by newborn screening using tandem mass spectrometry. (See
         <a class="medical medical_review" href="/z/d/html/4980.html" rel="external">
          "Overview of newborn screening"
         </a>
         .)
        </p>
        <p>
         Biochemical findings that may be present in amino acid disorders include metabolic acidosis, hyperammonemia, hypoglycemia with appropriate or increased ketosis, liver dysfunction, and the presence of reducing substances in the urine  (
         <a class="graphic graphic_table graphicRef76373" href="/z/d/graphic/76373.html" rel="external">
          table 8
         </a>
         ) [
         <a href="#rid4">
          4,5
         </a>
         ].
        </p>
        <p>
         Confirmation of diagnosis involves measurement of quantitative plasma amino acids and qualitative urine organic acids and enzyme analysis  (
         <a class="graphic graphic_table graphicRef73440" href="/z/d/graphic/73440.html" rel="external">
          table 9
         </a>
         ) [
         <a href="#rid4">
          4,6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Organic acidemias
         </span>
         <span class="headingEndMark">
          —
         </span>
         Organic acidemias, also known as organic acidurias, are characterized by accumulation of abnormal (and usually toxic) organic acid metabolites and increased excretion of organic acids in the urine [
         <a href="#rid7">
          7
         </a>
         ]. A variety of disorders may result in abnormal urine organic acid profiles, including organic acidemias, phenylketonuria, maple syrup urine disease, certain fatty acid oxidation disorders, disorders of ketogenesis, and mitochondrial disorders  (
         <a class="graphic graphic_table graphicRef50227" href="/z/d/graphic/50227.html" rel="external">
          table 10
         </a>
         ). Examples of organic acidemias include methylmalonic acidemia and propionic acidemia. (See
         <a class="medical medical_review" href="/z/d/html/2927.html" rel="external">
          "Organic acidemias: An overview and specific defects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112468.html" rel="external">
          "Methylmalonic acidemia"
         </a>
         .)
        </p>
        <p>
         Most organic acidemias become clinically apparent during the newborn period or early infancy. After an initial period of well-being, affected children develop a life-threatening episode of metabolic decompensation with poor feeding, vomiting, and lethargy. The symptoms may progress if not recognized and treated promptly. In older children, developmental delay or regression is usually present.
        </p>
        <p>
         Characteristic biochemical findings of organic acidemias include metabolic acidosis with increased anion gap, mild-to-moderate hyperammonemia, sepsis-like features secondary to bone marrow suppression, and ketosis [
         <a href="#rid4">
          4,5,7
         </a>
         ]. Other biochemical findings that may be present include hypoglycemia, liver dysfunction, and secondary carnitine deficiency  (
         <a class="graphic graphic_table graphicRef76373" href="/z/d/graphic/76373.html" rel="external">
          table 8
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Confirmation of diagnosis involves measurement of quantitative plasma amino acids and qualitative urine organic acids and also may include acylcarnitine profile and enzyme analysis [
         <a href="#rid4">
          4,8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Urea cycle disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         The urea cycle is the metabolic pathway that transforms nitrogen to urea for excretion from the body  (
         <a class="graphic graphic_figure graphicRef60652" href="/z/d/graphic/60652.html" rel="external">
          figure 1
         </a>
         ). Deficiency of any of the enzymes in the pathway causes a UCD. Examples of UCDs include ornithine transcarbamylase deficiency and citrullinemia. (See
         <a class="medical medical_review" href="/z/d/html/2929.html" rel="external">
          "Urea cycle disorders: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2923.html" rel="external">
          "Urea cycle disorders: Management"
         </a>
         .)
        </p>
        <p>
         UCDs often present in newborns who are initially well and become hyperammonemic after a period of protein feeding. However, patients with partial enzyme activity may present later. The characteristic biochemical findings of urea cycle defects include hyperammonemia, respiratory alkalosis, and ketosis  (
         <a class="graphic graphic_table graphicRef76373" href="/z/d/graphic/76373.html" rel="external">
          table 8
         </a>
         ). Liver dysfunction may be present [
         <a href="#rid4">
          4,5
         </a>
         ]. The diagnosis of UCDs is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2929.html" rel="external">
          "Urea cycle disorders: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Carbohydrate disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Disorders of carbohydrate metabolism can lead to hypoglycemia, liver dysfunction, myopathy, and/or cardiomyopathy. These disorders include deficiencies of enzymes in the pathways of the metabolism of glycogen  (
         <a class="graphic graphic_figure graphicRef81164" href="/z/d/graphic/81164.html" rel="external">
          figure 2
         </a>
         ), galactose  (
         <a class="graphic graphic_figure graphicRef50614" href="/z/d/graphic/50614.html" rel="external">
          figure 3
         </a>
         ), and fructose. Examples of carbohydrate disorders include galactosemia and the glycogen storage diseases  (
         <a class="graphic graphic_table graphicRef56040" href="/z/d/graphic/56040.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2928.html" rel="external">
          "Galactosemia: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2941.html" rel="external">
          "Overview of inherited disorders of glucose and glycogen metabolism"
         </a>
         .)
        </p>
        <p>
         Children with disorders of carbohydrate metabolism may present with lethargy, encephalopathy, and hypoglycemia during times of decreased carbohydrate intake or fasting. Hepatomegaly is sometimes present [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The characteristic biochemical findings of carbohydrate disorders include hypoglycemia and ketosis  (
         <a class="graphic graphic_table graphicRef76373" href="/z/d/graphic/76373.html" rel="external">
          table 8
         </a>
         ). Metabolic acidosis, liver dysfunction, and nonglucose-reducing substances in the urine may be present [
         <a href="#rid4">
          4,5
         </a>
         ]. Nonglucose-reducing substances are usually present in disorders of carbohydrate intolerance (eg, galactosemia, hereditary fructose intolerance) and usually absent in disorders of glycogenolysis and gluconeogenesis.
        </p>
        <p>
         Confirmation of diagnosis of disorders of carbohydrate metabolism typically involves deoxyribonucleic acid (DNA) analysis and/or assay of enzyme activity in cultured skin fibroblasts, liver, white blood cells, or red blood cells [
         <a href="#rid4">
          4,8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Fatty acid oxidation disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mitochondrial fatty acid oxidation plays an important role in energy production, particularly during fasting [
         <a href="#rid9">
          9
         </a>
         ]. Examples of fatty acid oxidation disorders include medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, fatty acid transportation defects, and defects of beta-oxidation enzymes  (
         <a class="graphic graphic_table graphicRef114663" href="/z/d/graphic/114663.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/111790.html" rel="external">
          "Overview of fatty acid oxidation disorders"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5801.html" rel="external">
          "Causes of hypoglycemia in infants and children"
         </a>
         .)
        </p>
        <p>
         Children with disorders of fatty oxidation metabolism may present with lethargy and encephalopathy during times of decreased carbohydrate intake or fasting. Hepatomegaly is sometimes present [
         <a href="#rid3">
          3
         </a>
         ]. Characteristic biochemical features of fatty acid oxidation disorders include hypoglycemia with inappropriately absent ketosis and liver dysfunction  (
         <a class="graphic graphic_table graphicRef76373" href="/z/d/graphic/76373.html" rel="external">
          table 8
         </a>
         ) [
         <a href="#rid4">
          4,5
         </a>
         ]. Hyperammonemia and metabolic acidosis also may occur.
        </p>
        <p>
         Diagnosis of fatty acid oxidation disorders involves plasma acylcarnitine analysis followed by confirmation through enzyme or in vitro assay in cultured skin fibroblasts or other specialized diagnostic testing, such as DNA analysis [
         <a href="#rid4">
          4,8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Mitochondrial disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         The frequency of recognition of disorders of mitochondrial metabolism is increasing [
         <a href="#rid10">
          10,11
         </a>
         ]. Within the mitochondria, organic acids, fatty acids, and amino acids are metabolized to acetyl-CoA, which condenses with oxaloacetate to form citric acid, which is oxidized in the Krebs cycle  (
         <a class="graphic graphic_figure graphicRef67253" href="/z/d/graphic/67253.html" rel="external">
          figure 4
         </a>
         ). Mitochondrial disorders can affect muscle alone, muscle and brain, or multiple systems with variable involvement of the heart, kidney, liver, skeletal muscle, or brain. The genetics and clinical manifestations of defects of the respiratory chain are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5151.html" rel="external">
          "Mitochondrial myopathies: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
         Examples of mitochondrial disorders include  (
         <a class="graphic graphic_table graphicRef69937" href="/z/d/graphic/69937.html" rel="external">
          table 3
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cytochrome c oxidase deficiency (see
         <a class="medical medical_review" href="/z/d/html/6151.html" rel="external">
          "Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn", section on 'Cytochrome c oxidase deficiency'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kearns-Sayre syndrome (see
         <a class="medical medical_review" href="/z/d/html/6271.html" rel="external">
          "Myopathies affecting the extraocular muscles in children", section on 'Kearns-Sayre syndrome'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Children with mitochondrial disorders may present with skeletal or visceral abnormalities, poor feeding, vomiting, cardiomyopathy, myopathy, liver failure, seizures, central nervous system abnormalities, developmental delay, retinopathy, blindness, deafness, focal neurologic findings (such as choreoathetosis), or renal Fanconi syndrome [
         <a href="#rid3">
          3,5,10
         </a>
         ]. Kidney involvement is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6121.html" rel="external">
          "Etiology and clinical manifestations of renal tubular acidosis in infants and children", section on 'Fanconi syndrome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2329.html" rel="external">
          "Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis", section on 'Proximal (type 2) renal tubular acidosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6121.html" rel="external">
          "Etiology and clinical manifestations of renal tubular acidosis in infants and children", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
         Biochemical features of mitochondrial disorders may include metabolic acidosis, lactic acidosis, hypoglycemia with appropriate or increased ketosis, and liver dysfunction  (
         <a class="graphic graphic_table graphicRef76373" href="/z/d/graphic/76373.html" rel="external">
          table 8
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Confirmation of diagnosis of mitochondrial disorders may involve either assay of enzyme activity in cultured skin fibroblasts, muscle, or liver or DNA testing [
         <a href="#rid4">
          4,8
         </a>
         ]. Muscle biopsy for routine histology and electron microscopy and magnetic resonance imaging (MRI) and/or spectroscopy of the brain may be helpful in diagnosis.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Peroxisomal disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Numerous catabolic and anabolic functions in cellular metabolism occur in peroxisomes. Catabolic functions include beta-oxidation of very long chain fatty acids (VLCFAs); oxidation of pipecolic, phytanic, pristanic, and many dicarboxylic acids; and degradation of hydrogen peroxide by catalase. Anabolic functions include synthesis of bile acids and plasmalogen (an important component of cell membranes and myelin).
        </p>
        <p>
         Peroxisomal disorders are a heterogeneous group of IEM that result in impairment of peroxisome function. Some features of peroxisomal disorders include microcephaly, dysmorphic facial features, hepatomegaly, hypotonia, and neurologic dysfunction to a varying extent. Examples of peroxisomal disorders include Zellweger syndrome and adrenoleukodystrophy  (
         <a class="graphic graphic_table graphicRef74261" href="/z/d/graphic/74261.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/6147.html" rel="external">
          "Peroxisomal disorders"
         </a>
         .)
        </p>
        <p>
         The diagnosis of peroxisomal disorders may be suspected in patients with an increased plasma concentration of VLCFA and/or phytanic acid. Confirmation requires specialized testing. (See
         <a class="medical medical_review" href="/z/d/html/6147.html" rel="external">
          "Peroxisomal disorders", section on 'Diagnosistic approach'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Lysosomal storage disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lysosomes are cytoplasmic, single membrane-bound organelles that contain enzymes responsible for the degradation of a variety of compounds including mucopolysaccharides, sphingolipids, and glycoproteins. Deficient activity of specific enzymes leads to progressive accumulation of partially degraded material, leading to distention of the cell, disruption of cellular function, and, sometimes, failure of active transport of small molecules from the lysosomes [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Lysosomal storage disorders (sometime called "storage diseases") are caused by defective lysosomal metabolism or export of naturally occurring compounds that leads to accumulation of various glycosaminoglycans, glycoproteins, or glycolipids within lysosomes of various tissues  (
         <a class="graphic graphic_table graphicRef63392" href="/z/d/graphic/63392.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Lysosomal storage diseases can be subdivided according to the involved compound or pathway as follows [
         <a href="#rid4">
          4,7
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mucopolysaccharidoses (eg, Hurler syndrome). (See
         <a class="medical medical_review" href="/z/d/html/2931.html" rel="external">
          "Mucopolysaccharidoses: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sphingolipidoses (eg, GM1 [monosialotetrahexosylganglioside] gangliosidosis, Tay-Sachs disease, Fabry disease, Gaucher disease, Niemann-Pick disease, Krabbe disease, metachromatic leukodystrophy, multiple sulfatase deficiency) [
         <a href="#rid13">
          13
         </a>
         ]. Several of these disorders are discussed in detail separately. (See appropriate topic reviews.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glycoproteinoses (eg, mannosidosis, sialidosis). (See
         <a class="medical medical_review" href="/z/d/html/6234.html" rel="external">
          "Overview of the hereditary ataxias", section on 'Sialidosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disorders of lysosomal enzyme transport (eg, mucolipidoses).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lysosomal membrane transport disorders (eg, sialic acid storage disease, cystinosis). (See
         <a class="medical medical_review" href="/z/d/html/6139.html" rel="external">
          "Cystinosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other (eg, lysosomal acid lipase deficiency). (See
         <a class="medical medical_review" href="/z/d/html/5813.html" rel="external">
          "Causes of primary adrenal insufficiency in children", section on 'Defects in cholesterol biochemistry'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The clinical manifestations vary depending upon the location and extent of storage that occurs but may include progressive hepatomegaly, splenomegaly, neurologic regression, short stature, coarsening of facial features, limitation/restriction of small and large joints, peripheral neuropathy, and/or ataxia [
         <a href="#rid3">
          3,14
         </a>
         ]. Diagnosis of these disorders usually requires specific enzyme assay on samples of white blood cells, serum, or skin fibroblasts [
         <a href="#rid4">
          4,8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Purine and pyrimidine disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Purine and pyrimidine nucleotides are important constituents of ribonucleic acid (RNA), DNA, nucleotide sugars and other high-energy compounds, and cofactors, such as adenosine triphosphate (ATP) and nicotinamide adenine dinucleotide (NAD) [
         <a href="#rid15">
          15
         </a>
         ]. The clinical presentation of disorders of purine and pyrimidine metabolism varies widely and may include renal calculi, neurologic dysfunction, delayed physical and mental development, self-mutilation, hemolytic anemia, and immune deficiency. Examples include Lesch-Nyhan disease, gout, and adenosine deaminase deficiency. (See
         <a class="medical medical_review" href="/z/d/html/1667.html" rel="external">
          "Clinical manifestations and diagnosis of gout"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3907.html" rel="external">
          "Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Porphyrias
         </span>
         <span class="headingEndMark">
          —
         </span>
         The porphyrias are genetic or acquired deficiencies in the activity of enzymes in the heme biosynthetic pathway. They are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7101.html" rel="external">
          "Porphyrias: An overview"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Metal metabolism disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Disorders of metal metabolism include hemochromatosis, Wilson disease, Menkes disease, and acrodermatitis enteropathica (zinc deficiency). These disorders are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemochromatosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3626.html" rel="external">
          "Wilson disease: Epidemiology and pathogenesis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1183398">
         <span class="h2">
          Congenital disorders of glycosylation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many enzymes, hormones, and other proteins require posttranslational glycosylation to function normally. This complex process of attaching sugars (oligosaccharides) to proteins occurs in the cytosol, endoplasmic reticulum, and Golgi apparatus and requires scores of different enzymes. Congenital disorders of glycosylation (CDGs) are caused by pathogenic variants in genes that encode the enzymes required for synthesis of these oligosaccharides [
         <a href="#rid16">
          16-20
         </a>
         ]. There is a wide range in age of onset of CDGs, although onset occurs most often in infancy. CDGs are typically multisystem disorders with varying clinical manifestations, depending upon the type of CDG. Manifestations include, but are not limited to, developmental delay, hypotonia, failure to thrive, hypoglycemia, and protein-losing enteropathy. CDGs are classified based upon the defect in the pattern of glycosylation and the affected gene. CDG Ia (phosphomannomutase 2 [PMM2]-CDG) is the most common type. CDG Ib (mannosephosphate isomerase [MPI]-CDG) is amenable to therapy with mannose. (See
         <a class="medical medical_review" href="/z/d/html/112030.html" rel="external">
          "Overview of congenital disorders of glycosylation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/126336.html" rel="external">
          "Specific congenital disorders of glycosylation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H321661">
         <span class="h2">
          Congenital disorders of creatine metabolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are three identified congenital metabolic disorders that lead to creatine deficiency. Two are autosomal recessive disorders that affect the biosynthesis of creatine. They are arginine:glycine amidinotransferase (AGAT) deficiency and guanidinoacetate methyltransferase (GAMT) deficiency. The third disorder, X-linked creatine transporter (CT) deficiency, is caused by a defect in the transport of creatine into the brain and muscle. These disorders are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/97126.html" rel="external">
          "Congenital disorders of creatine synthesis and transport"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3059887999">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120233.html" rel="external">
          "Society guideline links: Inborn errors of metabolism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Metabolic disorders typically result from the absence or abnormality of an enzyme or its cofactor or impaired transport of a biochemical, leading to either accumulation or deficiency of a specific metabolite. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The traditional classification system for inborn errors of metabolism (IEM) groups the disorders according to the general type of metabolism involved  (
         <a class="graphic graphic_table graphicRef82924" href="/z/d/graphic/82924.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef56040" href="/z/d/graphic/56040.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef69937" href="/z/d/graphic/69937.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef74261" href="/z/d/graphic/74261.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_table graphicRef63392" href="/z/d/graphic/63392.html" rel="external">
          table 5
         </a>
         and
         <a class="graphic graphic_table graphicRef114663" href="/z/d/graphic/114663.html" rel="external">
          table 6
         </a>
         ). The major categories of IEM include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Amino acid disorders (see
         <a class="local">
          'Amino acid disorders'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Organic acidemias (see
         <a class="local">
          'Organic acidemias'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Urea cycle defects (see
         <a class="local">
          'Urea cycle disorders'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Disorders of carbohydrate metabolism (see
         <a class="local">
          'Carbohydrate disorders'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fatty acid oxidation defects (see
         <a class="local">
          'Fatty acid oxidation disorders'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mitochondrial disorders (see
         <a class="local">
          'Mitochondrial disorders'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Peroxisomal disorders (see
         <a class="local">
          'Peroxisomal disorders'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lysosomal storage diseases (see
         <a class="local">
          'Lysosomal storage disorders'
         </a>
         above)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ferreira CR, Rahman S, Keller M, et al. An international classification of inherited metabolic disorders (ICIMD). J Inherit Metab Dis 2021; 44:164.
          </a>
         </li>
         <li class="breakAll">
          Saudubray JM, Charpentier C. Clinical phenotypes: Diagnosis/algorithms. In: Metabolic and molecular bases of inherited disease, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.1327.
         </li>
         <li class="breakAll">
          Wappner RS, Hainline BE. Introduction to inborn errors of metabolism. In: Oski's pediatrics. Principles and practice, 4th ed, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams and Wilkins, Philadelphia 2006. p.2145.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wappner RS. Biochemical diagnosis of genetic diseases. Pediatr Ann 1993; 22:282.
          </a>
         </li>
         <li class="breakAll">
          Weiner DL. Metabolic emergencies. In: Textbook of pediatric emergency medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott, Williams and Wilkins, Philadelphia 2006. p.1193.
         </li>
         <li class="breakAll">
          ACTion (ACT) sheets from the American College of Medical Genetics. http://www.acmg.net/AM/Template.cfm?Section=ACT_Sheets_and_Confirmatory_Algorithms&amp;Template=/CM/HTMLDisplay.cfm&amp;ContentID=5661 (Accessed on July 11, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindor NM, Karnes PS. Initial assessment of infants and children with suspected inborn errors of metabolism. Mayo Clin Proc 1995; 70:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamboj M. Clinical approach to the diagnoses of inborn errors of metabolism. Pediatr Clin North Am 2008; 55:1113.
          </a>
         </li>
         <li class="breakAll">
          Roe CR, Ding J. Mitochondrial fatty acid oxidation disorders. In: Metabolic and molecular bases of inherited disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.2297.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schapira AH. Mitochondrial diseases. Lancet 2012; 379:1825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfeffer G, Majamaa K, Turnbull DM, et al. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2012; :CD004426.
          </a>
         </li>
         <li class="breakAll">
          Wappner RS. Lysosomal storage disorders. In: Oski's pediatrics: Principles and practice, 4th ed, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.2199.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Platt FM. Sphingolipid lysosomal storage disorders. Nature 2014; 510:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wenger DA, Coppola S, Liu SL. Insights into the diagnosis and treatment of lysosomal storage diseases. Arch Neurol 2003; 60:322.
          </a>
         </li>
         <li class="breakAll">
          Wappner RS. Disorders of purine and pyrimidine metabolism. In: Oski's pediatrics: Principles and practice, 4th ed, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.2223.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woods AG, Woods CW, Snow TM. Congenital disorders of glycosylation. Adv Neonatal Care 2012; 12:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vodopiutz J, Bodamer OA. Congenital disorders of glycosylation--a challenging group of IEMs. J Inherit Metab Dis 2008; 31:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thiel C, Körner C. Therapies and therapeutic approaches in Congenital Disorders of Glycosylation. Glycoconj J 2013; 30:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goreta SS, Dabelic S, Dumic J. Insights into complexity of congenital disorders of glycosylation. Biochem Med (Zagreb) 2012; 22:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadat MA, Moir S, Chun TW, et al. Glycosylation, hypogammaglobulinemia, and resistance to viral infections. N Engl J Med 2014; 370:1615.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2930 Version 26.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33340416" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : An international classification of inherited metabolic disorders (ICIMD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33340416" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : An international classification of inherited metabolic disorders (ICIMD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33340416" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : An international classification of inherited metabolic disorders (ICIMD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8510995" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Biochemical diagnosis of genetic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8510995" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Biochemical diagnosis of genetic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8510995" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Biochemical diagnosis of genetic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7564553" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Initial assessment of infants and children with suspected inborn errors of metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18929055" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clinical approach to the diagnoses of inborn errors of metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18929055" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clinical approach to the diagnoses of inborn errors of metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22482939" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Mitochondrial diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22513923" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Treatment for mitochondrial disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22513923" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Treatment for mitochondrial disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24899306" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Sphingolipid lysosomal storage disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12633142" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Insights into the diagnosis and treatment of lysosomal storage diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12633142" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Insights into the diagnosis and treatment of lysosomal storage diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22469961" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Congenital disorders of glycosylation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18392739" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Congenital disorders of glycosylation--a challenging group of IEMs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22983739" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Therapies and therapeutic approaches in Congenital Disorders of Glycosylation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22838182" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Insights into complexity of congenital disorders of glycosylation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24716661" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Glycosylation, hypogammaglobulinemia, and resistance to viral infections.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
